The FDA has recently approved Vivaglobin, the first and only immunoglobin for subcutaneous (or under the skin) use. Unlike intravenous administration, which infuses medication into a vein, subcutaneous therapy uses a small needle that is inserted into the tissue just below the surface of the skin in one or more areas of the body (such as the stomach, thigh, upper arm, or hip). A small, portable pump controls the amount and rate of the infusion. With physician’s approval, patients or caregivers are able to administer therapy themselves, so there is no need to travel to a hospital, infusion center, or physician’s office for treatment, or to arrange to have a nurse present to administer therapy.

Subcutaneous infusions may be appropriate for patients who have small or collapsed veins (called poor venous access). Patients who have difficulty tolerating intravenous infusions may also be candidates for subcutaneous immunoglobulin. Because Vivaglobin is administered weekly, it may produce steady Ig levels in the blood.

For more information on CSL Behring's subcutaneous immunoglobulin product and its route of administration, please click on the link below.

To learn more about Vivaglobin^®, please visit www.Vivaglobin.com
Immune Globulin Subcutaneous (Human)

eNews Signup | CSL Plasma | Webmaster | Privacy | Terms of Use